Hsp90 inhibition sensitizes DLBCL cells to cisplatinLinnéa Schmidt, Karen Dybkær, Jonas Laugård Hald et al.|Cancer Chemotherapy and Pharmacology|2022Cited by 15
CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell LymphomaIssa Ismail Issa, Karen Dybkær, Hanne Due et al.|Cancers|2024Cited by 6
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myelomaIssa Ismail Issa, Karen Dybkær, Martin Bøgsted et al.|Cancer Drug Resistance|2020Cited by 1